Cancer Metabolism Based Therapeutics Market

Cancer Metabolism Based Therapeutics, 2017-2030

  • Lowest Price Guaranteed From USD 2,499

  • Companies Covered
    185

  • Pages
    263

  • View Count
    9217

Cancer Metabolism based Therapeutics Market Overview

The global cancer metabolism based therapeutics market to increase from $0.3 million to $2.2 billion by 2030, growing at a CAGR of 99%. Cancer metabolism is based on the principle that cancer cells, as compared to normal cells, have different metabolic activities in order to support their enhanced energy and anabolic requirements. The pioneering discovery by Otto Warburg in the middle of the 20th century led to the observation that metabolic activity in tumor tissues leads to a ten-fold increase in production of lactate (from glucose) under aerobic conditions. This revelation generated a significant interest and led industry stakeholders to target metabolic pathways in an effort to find the treatment of cancer. In addition, several academic players have also initiated studies to explore the functional consequences of alterations in various metabolic pathways.

The idea behind therapeutic strategies that target cancer metabolism is to limit / modulate the supply of crucial nutrients in cancer cells in order to induce cell death. Over the years, experimental and conceptual advances in this field have resulted in a better understanding of the role of metabolic pathways for the treatment of cancer. Owing to the complex nature of these pathways, innovation in cancer metabolism based therapeutics market has been gradual. However, the knowledge that metabolic adaptations in cancer cells promote their malignant properties has led to the development of novel therapeutic approaches for cancer treatment; selective inhibition of altered metabolic pathways in cancer cells is believed to be a highly promising approach.

Currently, there are several molecules that are under preclinical and clinical evaluation. Extensive research is currently being carried out to explore the potential of certain enzymes of metabolic pathways to act as targets for the treatment of cancer. The alterations in metabolic pathways in cancer cells are often mediated by mutations in oncogenes and cell signaling pathways. However, with the recognition of specific enzymes within each metabolic pathway, it is anticipated that drugs targeting these enzymes are likely to have high efficacy in treating cancer with minimal side-effects.

Despite the fact that the field of cancer metabolism based therapeutics market is still in early stages, there are many active players in this area. A larger proportion of players (on the basis of number of molecules) are small-sized and start-up companies. In fact, well-known big pharma companies have come together with smaller players to support discovery and development of such therapies. Our research indicates that there are several players with mid / late-stage clinical candidates that are likely to enter the market in the coming decade; examples include Agios Pharmaceuticals, Celgene, Polaris Group, Bio-Cancer Treatment International, BERG Health, Cornerstone Pharmaceuticals, Taiho Pharmaceutical, Novartis and 3-V Biosciences.

A number of strategic and research collaborations have been inked between companies to progress research activities in this area. As clinical stage candidates progress towards advanced stages of development and companies continue to receive monetary support from different stakeholders, we expect the cancer metabolism based therapeutics market is likely to witness substantial market growth during the forecast period.

Scope of the Report

The Cancer Metabolism Based Therapeutics Market, 2017-2030 market report provides an extensive study on the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the cancer metabolism based therapeutics market.

The primary focus is on drugs that lead to metabolic reprogramming in cancer cells by altering / inhibiting the activity of key enzymes / transporters that are a part of glucose metabolism, amino acid metabolism, TCA cycle, lipid metabolism, nucleotide metabolism and pentose phosphate pathway. The scope includes novel products that are being specifically developed to target altered metabolic pathways and key enzymes / amino acids involved in the metabolism of cancer cells. Examples of such enzymes / amino acids include isocitrate dehydrogenase 1 mutant (IDH 1), arginine, glutamine, MTH1, L-type amino acid transporter 1 (LAT1), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB3), choline kinase (ChoK), glucose transporter-1 (Glut-1) and hexokinase II. Specifically, certain drugs based on amino acid metabolism are being developed under the class of immuno-oncology drugs; these have been excluded from the scope of this document.

The overall pipeline comprises of 48 molecules that are under development for the treatment of a variety of oncological indications. Of these, 20 molecules are undergoing clinical evaluation while others (28) are in discovery / preclinical stages. This unexploited and promising market has its hopes pinned on multiple start-ups and small-sized companies, which have received significant financial support from strategic investors and venture capital firms in the recent past. Amongst other elements, the market report provides information on:

  • The current state of the market with respect to key players, phase of development of pipeline products (both clinical and preclinical / discovery), target enzymes / metabolic pathways and the key disease indications.
  • Comprehensive profiles of the clinical stage (phase III, phase II/III, phase II, phase II (planned)) molecules highlighting details on development of the drug, clinical trials, clinical trial endpoints, key preclinical / clinical findings, developer details including their financial performance (if available) and future market opportunity.
  • Various investments and grants received by companies focused in this area in order to accelerate and support their R&D activities.
  • Partnerships that have taken place in the recent past covering product development / commercialization agreements, research collaborations, clinical trial collaborations, license agreements, mergers / acquisitions and other such deals signed between stakeholders in the industry or with non-industrial players.
  • Distribution of the pipeline through a schematic funnel analysis, an overview of the landscape of industry developers (small, mid-sized and large players) and the geographical distribution of the companies involved in the development of cancer metabolism therapeutics.
  • Key targets, shortlisted based on dot-plot analysis, three-dimensional bubble analysis and five-dimensional spider-web analysis. Relevant parameters such as number of publications, grant programs, number of clinical trials, phase of development, and number of companies developing drugs for specific targets were considered for these analyses.

The key objective of cancer metabolism based therapeutics market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for cancer metabolism based therapeutics market during the forecast period. The market report provides a detailed market forecast and opportunity analysis from 2017 to 2030. The research, analysis and insights presented in this market research report are backed by a detailed understanding of the therapies targeting cancer metabolism and other targets closely associated with them. To account for uncertaintiesassociated with the development of novel therapeutics and add robustness to our model, we have provided three scenarios for our market forecast, namely the conservative, base and optimistic scenarios. All actual figures have been sourced and analyzed from publicly available information forums and from primary research. All financial figures mentioned in this market research report are in USD, unless otherwise specified.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com